We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

16 hedge funds and large institutions have $1.31M invested in Moleculin Biotech in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

19% more capital invested

Capital invested by funds: $1.1M → $1.31M (+$204K)

14% more funds holding

Funds holding: 14 → 16 (+2)

0.1% more ownership

Funds ownership: 0.54% → 0.65% (+0.1%)

Holders
16
Holders Change
+2
Holders Change %
+14.29%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$386K
2
Renaissance Technologies
Renaissance Technologies
New York
+$31.7K
3
Truist Financial
Truist Financial
North Carolina
+$30.3K
4
LPL Financial
LPL Financial
California
+$6.77K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.98K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$37.5K
2
TRCT
Tower Research Capital (TRC)
New York
-$577
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$824K +$386K +5,360 +86%
Vanguard Group
2
Vanguard Group
Pennsylvania
$203K -$37.5K -521 -15%
LPL Financial
3
LPL Financial
California
$103K +$6.77K +94 +7%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$62K +$5.98K +83 +11%
BlackRock
5
BlackRock
New York
$35.4K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$31.2K +$31.7K +440 New
Truist Financial
7
Truist Financial
North Carolina
$29.8K +$30.3K +420 New
AWM
8
Atticus Wealth Management
Florida
$9.47K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$5.14K -$577 -8 -10%
NFSG
10
Newbridge Financial Services Group
Florida
$3.88K – – –
Morgan Stanley
11
Morgan Stanley
New York
$1.27K +$72 +1 +6%
Bank of America
12
Bank of America
North Carolina
$406 +$360 +5 +500%
SSB
13
Sandy Spring Bank
Maryland
$253 – – –
CFO
14
CVA Family Office
Colorado
$97 – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$65 – – –
NSIM
16
North Star Investment Management
Illinois
$48 – – –
DB
17
Danske Bank
Denmark
$6 – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$3 – – –

MBRX Hedge Fund Activity: Q3 2024 in Review

16 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2024, worth a combined $1.31M — up 19% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MBRX positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, adding an estimated $386K. The largest seller was Vanguard Group, cutting an estimated $37.5K.

  • 16 institutional investors held Moleculin Biotech (MBRX) as of Q3 2024, up from 14 in Q2 2024.
  • Funds reported $1.31M of Moleculin Biotech stock for Q3 2024, up 19% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q3 2024 and 0 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q3 2024 was Armistice Capital, an estimated $386K added.
  • The largest Moleculin Biotech seller in Q3 2024 was Vanguard Group, an estimated $37.5K sold.

Based on aggregated 13F filings for Q3 2024.